Neonatal lupus erythrematosus overview: Difference between revisions
Jump to navigation
Jump to search
Mahmoud Sakr (talk | contribs) No edit summary |
Mahmoud Sakr (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{MS}} | {{CMG}}; {{AE}} {{MS}} | ||
==Overview== | |||
Neonatal lupus erythrematosus is an autoimmune disease that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily [[systemic lupus erythematosus]] and [[Sjögren’s syndrome]], and antibodies to SSA/Ro and/or SSB/La.<ref name="pmid20012231">{{cite journal| author=Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J| title=Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. | journal=Clin Rev Allergy Immunol | year= 2011 | volume= 40 | issue= 1 | pages= 27-41 | pmid=20012231 | doi=10.1007/s12016-009-8190-6 | pmc=PMC3558034 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20012231 }} </ref><ref name="pmid19852749">{{cite journal| author=Buyon JP| title=Updates on lupus and pregnancy. | journal=Bull NYU Hosp Jt Dis | year= 2009 | volume= 67 | issue= 3 | pages= 271-5 | pmid=19852749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19852749}} </ref>. It is characterized by cutaneous, cardiac or rarely both clinical manifestations. The skin manifestations are seen at least in 30% of these patients, in the form of periorbital annular erythematous plaques later spreading to other areas of face, scalp, trunk and extremities which is non-scarring and non-atrophic. This is usually transient lasting for days to months. But, the cardiac manifestations are seen in up to 60% of the patients is mainly in the form of complete congenital heart block which is irreversible and is associate with cardiomyopathy in at least 10% of the cases. Cardiomyopathy is associated with increased morbidity and mortality. Almost all the patients having cardiac lupus require permanent pacemaker. The recurrence rate of neonatal lupus is as much as 25% in the subsequent pregnancies. | Neonatal lupus erythrematosus is an autoimmune disease that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily [[systemic lupus erythematosus]] and [[Sjögren’s syndrome]], and antibodies to SSA/Ro and/or SSB/La.<ref name="pmid20012231">{{cite journal| author=Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J| title=Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. | journal=Clin Rev Allergy Immunol | year= 2011 | volume= 40 | issue= 1 | pages= 27-41 | pmid=20012231 | doi=10.1007/s12016-009-8190-6 | pmc=PMC3558034 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20012231 }} </ref><ref name="pmid19852749">{{cite journal| author=Buyon JP| title=Updates on lupus and pregnancy. | journal=Bull NYU Hosp Jt Dis | year= 2009 | volume= 67 | issue= 3 | pages= 271-5 | pmid=19852749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19852749}} </ref>. It is characterized by cutaneous, cardiac or rarely both clinical manifestations. The skin manifestations are seen at least in 30% of these patients, in the form of periorbital annular erythematous plaques later spreading to other areas of face, scalp, trunk and extremities which is non-scarring and non-atrophic. This is usually transient lasting for days to months. But, the cardiac manifestations are seen in up to 60% of the patients is mainly in the form of complete congenital heart block which is irreversible and is associate with cardiomyopathy in at least 10% of the cases. Cardiomyopathy is associated with increased morbidity and mortality. Almost all the patients having cardiac lupus require permanent pacemaker. The recurrence rate of neonatal lupus is as much as 25% in the subsequent pregnancies. | ||
==Pathophysiology== | |||
==Differentiating Pericarditis from other Diseases== | |||
==Epidemiology and Demographics== | |||
==Natural History, Complications and Prognosis== | |||
==Diagnosis== | |||
===History and Symptoms=== | |||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===EKG=== | |||
===Echocardiography=== | |||
==Treatment== | |||
===Medical Therapy=== | |||
===Surgery=== | |||
==References== | ==References== | ||
Revision as of 21:04, 23 August 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahmoud Sakr, M.D. [2]
Overview
Neonatal lupus erythrematosus is an autoimmune disease that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La.[1][2]. It is characterized by cutaneous, cardiac or rarely both clinical manifestations. The skin manifestations are seen at least in 30% of these patients, in the form of periorbital annular erythematous plaques later spreading to other areas of face, scalp, trunk and extremities which is non-scarring and non-atrophic. This is usually transient lasting for days to months. But, the cardiac manifestations are seen in up to 60% of the patients is mainly in the form of complete congenital heart block which is irreversible and is associate with cardiomyopathy in at least 10% of the cases. Cardiomyopathy is associated with increased morbidity and mortality. Almost all the patients having cardiac lupus require permanent pacemaker. The recurrence rate of neonatal lupus is as much as 25% in the subsequent pregnancies.
Pathophysiology
Differentiating Pericarditis from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
EKG
Echocardiography
Treatment
Medical Therapy
Surgery
References
- ↑ Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J (2011). "Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies". Clin Rev Allergy Immunol. 40 (1): 27–41. doi:10.1007/s12016-009-8190-6. PMC 3558034. PMID 20012231.
- ↑ Buyon JP (2009). "Updates on lupus and pregnancy". Bull NYU Hosp Jt Dis. 67 (3): 271–5. PMID 19852749.